Clinical trial
Immunogenicity and Safety of Pentaxim in South African Infants
NCT00254969 · Sanofi, Industry · Completed
Key facts
| NCT number | NCT00254969 |
|---|---|
| Title | Immunogenicity and Safety of Pentaxim in South African Infants |
| Lead sponsor | Sanofi, Industry |
| Status | Completed |
| Phase | Phase 3 |
| Study type | Interventional |
| Conditions | Diphtheria, Tetanus, Haemophilus Infections, Pertussis, Poliomyelitis |
| Intervention type | Biological |
| Interventions | Diphtheria, Tetanus, Polio, Acellular Pertussis and Hib |
| Enrollment | 212 |
| Start date | Oct 1, 2005 |
| Primary completion | May 1, 2008 |
| Completion | Jan 1, 2010 |
| First posted | Nov 17, 2005 |
| Last update posted | Apr 17, 2012 |
| Countries | South Africa |
At a glance
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: